|
|
420 Lexington Avenue Suite 450 New York, NY 10170 USA phone:212-584-4180 fax:646-514-7787
|
|
| Symbol |
NBS |
| Exchange |
AMEX |
| Founded |
2006 |
| Employees |
600 |
|
|
| www.neostem.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| International biopharmaceutical company with a leading position as a stem cell based company with both manufacturing and therapeutic divisions. |
 |
| Management |
| Robin Smith, MD MBA, CEO & Chairman of the Board;
Jason Kolbert, MBA, Vice President, Strategic Business Development |
| |
|
|
|
|
|
|
|
| Keywords |
| Stem cell harvesting, stem cell bank, China |
|
|
|
| Description |
|
NeoStem, Inc. is an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units: (i) U.S. adult stem cells, (ii) China adult stem cells, (iii) China pharmaceuticals. These business units are expected to provide platforms for the accelerated development and commercialization of innovative technologies and products in both the U.S. and China. |
 |
| Products / Services |
Stem Cell Therapy
Stem Cell Banking
Manufacturing of Generic Pharmaceuticals
|
 |
| Technology / Differentiation |
| A significant development by Neostem has been a technological platform to harvest and then preserve an individual's stem cells, thereby serving as a stem cell bank for customers. The company's proprietary technology, including the very small embryonic stem cell VSEL(TM) Technology, enables the harvesting of a patient's stem cells by a simple procedure and then enables the cryo-preservation of the harvested stem cells for storage. |
 |
| Market / Customers |
Adults in US & China
Over 150 Billion Dollars annual business worldwide
stem cell therapy and pharmaceuticals in China
|
 |
| Status |
| Revenue generating with drugs in pipeline, clinical trials and mature stem cell therapy with early stage stem cell research and development. |
 |
|
|
|
|
|
|